Shanghai, March 14, 2019, Elpiscience Biopharma, Ltd. announces its first Symposium on “Novel Targets for Cancer Immunotherapy”, which will be held on March 24th, at Shanghai Kempinski Hotel.
The field of Cancer Immunotherapy is advancing in a breathtaking speed. The first generation of immune check point antibodies such as PD1/PD-L1, CTLA4 antibodies have revolutionized clinical practice in many cancer types. However a majority of cancer patients can still not benefit from the first generation of IO drugs. Novel targets and innovative approaches are in urgent demand to meet the unmet medical needs. The symposium brings together world leaders in immuno-oncology, to explore new therapeutic targets and approaches, to inspire and open up game-changing paths for the next generation of cancer immunotherapies.
About Elpiscience
Elpiscience is a clinical stage biopharmaceutical company focusing on cancer immunotherapy. The company is committed to leading the innovation and development of the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpscience’s first therapeutic product ES101 has entered into clinical trial, and the second innovative product 欧洲杯买球网APP is IND ready. Elpiscience has a pipeline of more than 10 innovative molecules in discovery, covering a wide range of targets with a particular focus on innate immunity and tumor microenvironment. Elpiscience’s sustainable pipeline forms a strong cornerstone for developing the next generation and more effective immunotherapies. Founded and managed by seasoned executives in the biopharma industry, Elpiscience is backed by top investors such as Lilly Asia Ventures, Hillhouse Capital and CDH Investment.
Corporate Communications:
PR@elpiscience.com
Partnering:
BD@elpiscience.com
